
    
      This clinical investigation is a prospective, multi-center, randomized, double-blind study
      design enrolling 360 patients at 57 centers to demonstrate the safety and effectiveness of
      the therapy, the CONTAK RENEWAL 2/4/4HE devices and the EASYTRAK 2 lead.
    
  